Photo - Micronoma Inc.
48303

Micronoma Inc.

Early stage cancer detection by Microbiome and Liquid Biopsy

USA, California
Market: Medicine, Another, Artificial Intelligence
Stage of the project: Prototype or product is ready

Date of last change: 17.02.2021
Rating
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

Each year 9 million of people die of cancer. 4 million of these are preventable deaths, if we had early stage detection methods. The 3 founders of Micronoma are world renowned microbiome experts from UC San Diego. They moved away from current mostly human and tumor centric approach and discovered that tumors can be detected specifically and sensitively, even in its early stages, by using liquid biopsy targeting tumor microbial markers. Micronoma is dedicated to reduce the number of cancer preventable deaths with their novel tumor detection solutions.

Current Status

We are early stage and currently closing our first seed funding to be able to fully spin out of UC San Diego and start developing our lab test under CLIA services program. We expect to be in full operation in August.

Market

First 2 years will be focused on oncologists, pulmonologists and cancer centers in USA and EU. We will expand to the rest of the world starting in year 3 by partnering with local diagnostic service providers.

Problem or Opportunity

Clinical trial utility are expensive so we are taking a one cancer detection at a time approach. If we were able to get a larger amount of funding we can apply the same solution on at least 20 different cancer types simultaneously from one simple blood samples.

Solution (product or service)

Within the first 2 years, we will first reach north american and european market with a laboratory developed test perform in CLIA labs. We will then later deploy our offering under regulatory approved (PMA or CE IVD certification) more globally

Competitors

Liquid Biopsy (from Guardant or Foundation Medicine) are the closest competitors we would have already commercially available.
Grail or Thrive are currently having projects in development but much like the 2 previous companies they focus on tumor or somatic markers which likely explain their lack of sensitivity and specificity, specifically in early stage of cancer.

Advantages or differentiators

1- detect cancer in stage 1 or 2 to reduce preventable death
2- cancer specific - the test doesn't tell you if you have a marker of any cancer but rather specifically if you are a marker for lung cancer for example

Finance

Revenues are schedule to happen by end of year 2, and we expect to be cash flow positive by year 4.

Business model

We are going to offer our test to cancer centers, oncologists and pulmonologists, who will prescribe the test and provide us with a blood sample of patient to be tested.

Money will be spent on

Finalizing the test
Doing clinical utility trial

Won the competition and other awards

2020 Cool Companies
2021 Unicorn Battle Silicon Valley Winner

Product Video

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility111
star0
Add to favorites
Delete from favorites
share
close
thumb_up2
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video